<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2024.1401212</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Relationship between Contingent Negative Variation and afterimage duration in migraine patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Giesen</surname> <given-names>Simeon</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2686426/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Rimmele</surname> <given-names>Florian</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1235669/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>J&#x00FC;rgens</surname> <given-names>Tim P.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Scheidt</surname> <given-names>J&#x00F6;rg</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Drescher</surname> <given-names>Johannes</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Leonhardt</surname> <given-names>Ann-Kristin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Schulze</surname> <given-names>Sophia</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Harbeck</surname> <given-names>Birgit</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Meyer</surname> <given-names>Wolfgang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>M&#x00FC;ller</surname> <given-names>Britta</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/763226/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kropp</surname> <given-names>Peter</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/497600/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Keller</surname> <given-names>Armin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2722606/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Institute of Medical Psychology and Medical Sociology, University of Rostock Medical Center</institution>, <addr-line>Rostock</addr-line>, <country>Germany</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurology, University of Rostock Medical Center</institution>, <addr-line>Rostock</addr-line>, <country>Germany</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Neurology, KMG Hospital G&#x00FC;strow</institution>, <addr-line>G&#x00FC;strow</addr-line>, <country>Germany</country></aff>
<aff id="aff4"><sup>4</sup><institution>Institute for Informations Systems, University of Applied Sciences</institution>, <addr-line>Hof</addr-line>, <country>Germany</country></aff>
<aff id="aff5"><sup>5</sup><institution>III. Department of Medicine, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg</addr-line>, <country>Germany</country></aff>
<aff id="aff6"><sup>6</sup><institution>Amedes Experts, Endocrinology</institution>, <addr-line>Hamburg</addr-line>, <country>Germany</country></aff>
<aff id="aff7"><sup>7</sup><institution>Faculty of Medicine and Dentistry, Queen Mary University of London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff>
<author-notes>
<fn id="fn0001" fn-type="edited-by"><p>Edited by: Parisa Gazerani, Oslo Metropolitan University, Norway</p></fn>
<fn id="fn0002" fn-type="edited-by"><p>Reviewed by: Stefan Evers, University of M&#x00FC;nster, Germany</p>
<p>Angelo Torrente, University of Palermo, Italy</p></fn>
<corresp id="c001">&#x002A;Correspondence: Simeon Giesen, <email>SimeonDavid.Giesen@med.uni-rostock.de</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1401212</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Giesen, Rimmele, J&#x00FC;rgens, Scheidt, Drescher, Leonhardt, Schulze, Harbeck, Meyer, M&#x00FC;ller, Kropp and Keller.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Giesen, Rimmele, J&#x00FC;rgens, Scheidt, Drescher, Leonhardt, Schulze, Harbeck, Meyer, M&#x00FC;ller, Kropp and Keller</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Background</title>
<p>Abnormalities in electrocortical parameters and persistence of afterimage after visual stimulation are known to occur in migraine patients. The results of studies on Contingent Negative Variation (CNV) and afterimage persistence in migraine patients suggest a link between these two phenomena and a connection to the pathomechanism of migraine.</p>
</sec>
<sec id="sec2">
<title>Objectives</title>
<p>To date, no studies have investigated both afterimage duration and CNV parameters in the same subjects. The aim of this study was to investigate the relationship between the early component of CNV (iCNV) and the duration of the afterimage in migraine patients.</p>
</sec>
<sec id="sec3">
<title>Methods</title>
<p>Sixty seven migraine patients from the headache center of the University of Rostock Medical Center were examined for iCNV amplitude, iCNV habituation and afterimage duration. The subjects also completed questionnaires developed for this study and the MIDAS (Migraine Disability Assessment) questionnaire.</p>
</sec>
<sec id="sec4">
<title>Results</title>
<p>Associations were found between iCNV amplitude and afterimage duration and between habituation capacity and afterimage duration. A deficit in habituation capacity correlated with a significantly prolonged afterimage duration. Increased iCNV amplitude and prolonged afterimage duration were also significantly correlated.</p>
</sec>
<sec id="sec5">
<title>Conclusion</title>
<p>Conclusions about the pathophysiology of migraine can be drawn from the results of this study. The results support the hypothesis of cortical hyperexcitability as a consequence of a low pre-activation level, which may be a possible contributory cause of migraine. Furthermore, they allow assessment of whether the afterimage examination, which is easier and quicker to perform than the CNV examination, can be used as a diagnostic tool or as a parameter to monitor the course of therapy in people with migraine.</p>
</sec>
</abstract>
<kwd-group>
<kwd>migraine</kwd>
<kwd>after image</kwd>
<kwd>Contingent Negative Variation</kwd>
<kwd>pathomechanism</kwd>
<kwd>future migraine therapy</kwd>
<kwd>preemptive therapy</kwd>
</kwd-group>
<counts>
<fig-count count="6"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="65"/>
<page-count count="10"/>
<word-count count="7415"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Headache and Neurogenic Pain</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec6">
<label>1</label>
<title>Introduction</title>
<p>Migraine is a disease with a high prevalence (<xref ref-type="bibr" rid="ref1">1</xref>). A prevalence of 20% in women and 8% in men is assumed (<xref ref-type="bibr" rid="ref2">2</xref>). The disease is associated with a high level of distress (<xref ref-type="bibr" rid="ref3">3</xref>). The impairment caused by migraine is high, as are the restrictions on quality of life (<xref ref-type="bibr" rid="ref4">4</xref>). Thus, migraine is one of the 20 most common causes of disabling worldwide (<xref ref-type="bibr" rid="ref4">4</xref>). Comorbidities like major depression and panic disorder may accompany the disease (<xref ref-type="bibr" rid="ref5">5</xref>).</p>
<p>The pathomechanism of migraine is still not fully understood (<xref ref-type="bibr" rid="ref6">6</xref>, <xref ref-type="bibr" rid="ref7">7</xref>). Therefore, research into the pathomechanism and the effect of migraine medications plays an important role in improving future migraine therapy. Neuronal and vascular processes and the interplay between them lead to migraine (<xref ref-type="bibr" rid="ref8">8</xref>&#x2013;<xref ref-type="bibr" rid="ref12">12</xref>).</p>
<p>Various methods allow conclusions to be drawn about cortical information processing. For example, various tests can be used to determine changes in cortical excitability in migraine patients. One example is sound-induced flash illusions, in which visual and auditory stimuli are presented simultaneously and cognitive processing can be evaluated (<xref ref-type="bibr" rid="ref13">13</xref>).</p>
</sec>
<sec id="sec7">
<label>2</label>
<title>Contingent Negative Variation and afterimage duration</title>
<sec id="sec8">
<label>2.1</label>
<title>Contingent Negative Variation</title>
<p>Migraine patients are known to have a higher amplitude of slow negative cortical potentials compared to healthy individuals. Slow negative cortical potentials are electrical potential shifts that can be measured in the summation of the simultaneous potential changes of individual neurons using an EEG. They are measured when the subject is expecting an external stimulus. This can be demonstrated by studies on the Contingent Negative Variation (CNV) (<xref ref-type="bibr" rid="ref14">14</xref>&#x2013;<xref ref-type="bibr" rid="ref16">16</xref>). The Contingent Negative Variation, first described by Walter et al. in <italic>Nature</italic>, is an event-related, slow, negative cortical potential that occurs in individuals in an expectancy state. These potentials can be derived from an electrode positioned centrally on the scalp. It represents the planning of goal-directed behavior and is interpreted as attentional readiness (<xref ref-type="bibr" rid="ref17">17</xref>). Furthermore, a reduced habituation effect on the early component of CNV, the so-called iCNV amplitude, is observed when a stimulus is repeatedly presented to people with migraine (<xref ref-type="bibr" rid="ref15">15</xref>, <xref ref-type="bibr" rid="ref16">16</xref>). Regular monitoring of iCNV amplitude can help to predict future migraine attacks, which allows drug and non-drug interventions to be undertaken at an early stage (<xref ref-type="bibr" rid="ref18">18</xref>&#x2013;<xref ref-type="bibr" rid="ref20">20</xref>). However, so far this prediction has been applied exclusively in studies because the determination of CNV parameters is technically very complex and time-consuming.</p>
</sec>
<sec id="sec9">
<label>2.2</label>
<title>Afterimage duration</title>
<p>Besides the specificities regarding CNV components, migraine patients show a particularly long afterimage duration (<xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref21">21</xref>, <xref ref-type="bibr" rid="ref22">22</xref>). Afterimage duration is characterized by the persistence of an afterimage induced by a visual stimulus. The origin of afterimage effect may lie at the cortical level (<xref ref-type="bibr" rid="ref23">23</xref>, <xref ref-type="bibr" rid="ref24">24</xref>). While the majority of studies assume a prolonged afterimage effect in migraine patients, one study showed the opposite (<xref ref-type="bibr" rid="ref25">25</xref>).</p>
</sec>
<sec id="sec10">
<label>2.3</label>
<title>Links between CNV and afterimage duration</title>
<p>Both phenomena, <italic>CNV amplitude</italic> and <italic>afterimage duration</italic>, may provide insights into the pathomechanism of migraine. The hypothesis of a common etiological origin of the increased iCNV amplitude, the prolonged afterimage duration and the occurrence of headache can be derived from study results. People with migraine show a reduced cortical pre-activation level, which leads to a disturbance of the neuronal balance between inhibitory and excitatory processes and cortical information processing (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref27">27</xref>). As a result, neuronal hyperexcitability occurs in the presence of non-painful sensory stimuli. The phenomena of habituation deficit and increased iCNV amplitude are due to a reduced level of pre-activation (<xref ref-type="bibr" rid="ref26">26</xref>&#x2013;<xref ref-type="bibr" rid="ref31">31</xref>). Reduced cortical excitability requires greater synchronous activity of neurons to initiate the habituation mechanism. As a result, an habituation deficit and an increased iCNV amplitude are measured on average across all measurement series (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref33">33</xref>). Cortical hyperexcitability may be a cause of prolonged afterimage in migraine patients (<xref ref-type="bibr" rid="ref12">12</xref>). It leads to overactivation of the thalamus, which may be part of the pathogenesis of migraine (<xref ref-type="bibr" rid="ref34">34</xref>). Visual phenomena in migraine patients can be explained by an overactivation of the <italic>Corpus geniculatum laterale</italic> as a component of the thalamus and the visual pathway.</p>
</sec>
<sec id="sec11">
<label>2.4</label>
<title>Similarities in study results</title>
<p>Analogies between CNV amplitude and afterimage duration can be found. Kropp et al. demonstrated a decrease in iCNV amplitude with increasing age in subjects without migraine. This effect may be attributed to an increase in habituation with age, which can be interpreted as a sign of cerebral maturation. In people with migraine there was neither an increase in habituation nor a decrease in iCNV amplitude (<xref ref-type="bibr" rid="ref33">33</xref>). There is evidence that increasing age in healthy subjects is associated with a reduction of afterimage duration. Again, this phenomenon is not observed in migraine patients. There are only small differences in afterimage latency between people with migraine and healthy young subjects, whereas the difference increases with age (<xref ref-type="bibr" rid="ref12">12</xref>). As a result, the long afterimage duration in adult migraine patients might be an indication of altered cortical development and cerebral maturation&#x2014;just like the development of iCNV amplitude.</p>
<p>Considering the migraine cycle, the two phenomena of iCNV amplitude and longer afterimage duration depend on the migraine interval. The level of iCNV amplitude varies in relation to the migraine interval, allowing changes in iCNV amplitude to be measured over the progression of a migraine cycle. Increased iCNV amplitudes are measured during the interictal interval and especially one day before a migraine attack, while after a migraine attack these amplitudes are equal to or lower than those of healthy subjects (<xref ref-type="bibr" rid="ref18">18</xref>, <xref ref-type="bibr" rid="ref19">19</xref>, <xref ref-type="bibr" rid="ref32">32</xref>). Luedtke et al. observed a periodic development in the duration of afterimages. Longer afterimage durations were measured in preictal migraine patients compared to interictal migraine patients (<xref ref-type="bibr" rid="ref25">25</xref>). However, it should be noted that key findings of this study contradict those of other studies. In contrast to other studies on afterimage duration or other visual phenomena in migraine patients (<xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref21">21</xref>), Luedtke et al. found a less-pronounced afterimage duration in people with migraine compared to healthy subjects. The authors concluded a periodic change in the balance of cortical neuronal excitation and inhibition during migraine cycles (<xref ref-type="bibr" rid="ref25">25</xref>).</p>
<p>All these results were obtained in studies investigating either CNV parameter expression or afterimage duration in migraine patients. There is also a lack of studies investigating these phenomena in the same subjects.</p>
</sec>
</sec>
<sec sec-type="methods" id="sec12">
<label>3</label>
<title>Methods</title>
<sec id="sec13">
<label>3.1</label>
<title>Sample</title>
<p>Subjects were recruited from the headache center of the University of Rostock Medical Center. The study was approved by the ethics committee of the University of Rostock Medical Center (registration numbers: A 2011&#x2013;0029 and A 2017&#x2013;0187). Sixty seven patients with migraine with and without aura (maximum of 14 migraine days/month, disease duration at least one year, at least five migraine attacks prior to study participation) were examined. Diagnosis was made according to the third edition of the <italic>International Classification of Headache Disorders (ICHD-3)</italic>. Exclusion criteria were mental illness, pregnancy and medication overuse. Sample size requirements were derived from sample sizes in various studies of CNV and afterimage duration in people with migraine (<xref ref-type="bibr" rid="ref18">18</xref>, <xref ref-type="bibr" rid="ref35">35</xref>).</p>
</sec>
<sec id="sec14">
<label>3.2</label>
<title>Study design</title>
<p>Contingent Negative Variation and afterimage duration were measured in each participant (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In addition, participants completed a questionnaire designed for this study, including the number of migraine days, time since last migraine attack (in days), triggers and duration of the disease (in months). Migraine occurrence in the two-day period before and after the study was assessed using a pain diary, the questionnaire and telephone interviews. We only used data from people who had no migraine attack for at least two days before or after the study, because the amplitude of iCNV can be influenced by a migraine attack (<xref ref-type="bibr" rid="ref18">18</xref>, <xref ref-type="bibr" rid="ref19">19</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption><p>Study design.</p></caption>
<graphic xlink:href="fneur-15-1401212-g001.tif"/>
</fig>
<p>In addition, participants completed two other questionnaires. The HIT-6 (<italic>Headache Impact Test</italic>) is a questionnaire designed to assess headache-related impairment in migraine patients (<xref ref-type="bibr" rid="ref36">36</xref>) and measures the negative impact of headaches on daily life (<xref ref-type="bibr" rid="ref37">37</xref>). The test examines how people subjectively rate their well-being or pain, their ability to concentrate and any limitations in their daily activities (see questions on the HIT-6). A higher score indicates a greater degree of impairment due to pain. Scores can range from a minimum of 36 to a maximum of 78. Headache-related disability can also be assessed using the MIDAS (<italic>Migraine Disability Assessment</italic>), which consists of a scale ranging from grade I (little or no disability) up to five days of migraine to grade IV (severe disability) up to 21 or more days of migraine. The last three months are assessed (see MIDAS questions). While the HIT-6 score is mainly influenced by pain intensity, the MIDAS score is mainly influenced by the number of headache days (<xref ref-type="bibr" rid="ref38">38</xref>).</p>
</sec>
<sec id="sec15">
<label>3.3</label>
<title>Acquisition of CNV</title>
<p>CNV parameters were measured according to a previously developed protocol to ensure uniform test conditions (light, room atmosphere). The 10&#x2013;20 system published by Herbert Jasper in Science in 1935 (<xref ref-type="bibr" rid="ref39">39</xref>, <xref ref-type="bibr" rid="ref40">40</xref>) was used to determine the electrode positions. Before applying the electrodes, the skin sites were disinfected and coated with an electrically conductive paste supplied by NIHON KOHDEN. Ring electrodes coated with silver-silver chloride (Ag/AgCl) were used as electrodes. Six electrodes were used for each measurement: the area over the Cz (<italic>Central zero</italic>), two areas over the forehead (Fp1 and Fp2), two electrodes on the <italic>Process&#x016B;s mastoidei</italic> and one electrode for recording an electro-oculogram (EOG). Position Cz was used for data analysis. The two linked mastoid electrodes served as reference electrodes. The electrode on the forehead served as ground electrode. The remaining electrodes were used to detect artifacts of the <italic>Musculus orbicularis oculi</italic> or movements of the eyeballs.</p>
<p>The CNV measurement consisted of 32 Go and 8 NoGo trials. The Go trials consisted of an acoustic stimulus S1 (warning stimulus) with a frequency of 1,000&#x2009;Hz (medium-high pitch) and a duration of 100&#x2009;ms. After 3&#x2009;s, S1 was followed by the presentation of a sound S2 (imperative stimulus) with a frequency of 2,500&#x2009;Hz (high pitched tone) and a duration of up to 2,500&#x2009;ms. The subject had to respond to this second stimulus as quickly as possible by pressing a button, after which S2 was switched off. A <italic>NoGo section</italic>, to which the subject was not required to respond, consisted of an acoustic stimulus at a frequency of 200&#x2009;Hz (low frequency tone). This tone was not followed by an imperative stimulus. The presentation of the <italic>Go</italic> and <italic>NoGo stimuli</italic> was controlled by the <italic>E-Prime v2.0</italic> program (E-Prime, 2002) in randomized order. The CNV was derived using an EEG amplifier from <italic>Brain Products</italic>. The <italic>Brain Vision Recorder</italic> (version 1.20.0601) from <italic>Brain Products</italic> was used to record the data.</p>
<p>The measured electrocortical data were analyzed using the <italic>Brain Vision Analyzer</italic> (version 2.1.1.327) software from <italic>Brain Products</italic>. A high-pass filter (0.03281&#x2009;Hz, slope unit: 12&#x2009;dB/octave), a low-pass filter (30&#x2009;Hz, slope unit: 12&#x2009;dB/octave) and a band-stop filter (50&#x2009;Hz) were used to process the raw EEG data. During segmentation, 32 sequences of equal length were formed. The baseline correction was followed by a qualitative artifact correction in which sequences with high artifact content were removed after reviewing the 32 sequences. The number of rejected trials was recorded.</p>
<p>The iCNV amplitude was determined using the procedure described by B&#x00F6;cker et al. For this purpose, the respective amplitude maximum was determined in the time interval between 550 and 750&#x2009;ms after stimulus S1 presentation. The time of this maximum amplitude represents the center of a constructed time window that also included a time period of 100&#x2009;ms before and after the maximum. The mean amplitude during this time interval was defined as the iCNV amplitude (<xref ref-type="bibr" rid="ref33">33</xref>, <xref ref-type="bibr" rid="ref41">41</xref>).</p>
<p>To determine the habitability coefficient, 32 trials were assigned to eight blocks of four trials each. The amplitude levels in each block were averaged. If there were fewer than 32 trials left due to artifacts, eight blocks with fewer than four trials each were formed, taking care to ensure a homogeneous distribution of trials in the blocks. Finally, the habituation coefficient was determined by regression analysis. It was described by a linear equation of the form <italic>y&#x2009;=&#x2009;ax&#x2009;+&#x2009;b</italic> (a&#x2009;=&#x2009;slope parameter, b&#x2009;=&#x2009;intercept of the y-axis). Parameter a represents the slope parameter, which is closely related to the habituation coefficient, while parameter <italic>b</italic> describes the point of intersection with the y-axis. This approach corresponds to the procedure used in several studies (<xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref33">33</xref>).</p>
</sec>
<sec id="sec16">
<label>3.4</label>
<title>Acquisition of afterimage</title>
<p>The afterimage duration was determined - similar to other studies (<xref ref-type="bibr" rid="ref21">21</xref>, <xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref35">35</xref>) &#x2014; using an <italic>iPad Pro</italic> (Model A1584) with a display size of 12.9 inches (32.78&#x2009;cm screen diagonal) positioned 60&#x2009;cm away from the subject&#x2019;s eyes. A black circular ring with a cross in the center was presented to each patient for a period of 30&#x2009;s. After this period, the subject perceived an afterimage (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The subject was asked to report the time at which the afterimage disappeared completely. It should be noted that there was no eye blinking during this time, as this can affect the duration of the afterimage (<xref ref-type="bibr" rid="ref42">42</xref>). The duration of the afterimage was measured in seconds.</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption><p>Procedure of the afterimage duration test. The upper part of the figure shows the 30-s presentation of the visual stimulus. The lower part illustrates the appearance of the afterimage in the subject&#x2019;s perception after the visual stimulus disappeared.</p></caption>
<graphic xlink:href="fneur-15-1401212-g002.tif"/>
</fig>
<p>The expression of afterimage duration was determined according to a protocol established for this study. This allowed comparable conditions between subjects and between the first and second examination of each subject. A room with a quiet atmosphere and uniform lighting conditions was used for the study. The subjects sat on an examination chair in a relaxed position. All subjects were asked if they had any visual impairment that would have prevented them from adequately perceiving the visual stimulus.</p>
</sec>
<sec id="sec17">
<label>3.5</label>
<title>Statistical analysis</title>
<p><italic>SPSS</italic> (Version 27) was used for the statistical analysis of the data. Data were analyzed for all subjects not having migraine attacks 2&#x2009;days before and after the examination. This was determined by using questionnaires and telephone calls. All data used therefore originate from participants who were in the interictal interval. Parametric tests were used to test for normal distribution using the <italic>Kolmogorov&#x2013;Smirnov</italic> and <italic>Shapiro&#x2013;Wilk</italic> tests. In addition, the homogeneity of the distribution of demographic and disease-related characteristics in each sample was tested.</p>
<p>We divided the subjects into the two groups habituation/sensitization or long (&#x003E; 6&#x2009;s)/short (&#x003C; 6&#x2009;s) afterimage effect. Hypotheses were tested using ANOVA. As the hypotheses were directional, one-tailed tests were always performed and a probability of error of &#x003C;5% was assumed.</p>
</sec>
</sec>
<sec sec-type="results" id="sec18">
<label>4</label>
<title>Results</title>
<sec id="sec19">
<label>4.1</label>
<title>Distribution of demographic and disease-related characteristics</title>
<p><xref ref-type="table" rid="tab1">Table 1</xref> presents demographic and disease-related characteristics in subjects with differences in habituation expression. There are no significant differences between the two groups. Among the subjects with habituation, 37.5% had migraine with aura. Among the subjects with dishabituation, 42.9% had a migraine with aura. There is no significant difference in habituation between migraine patients with and without aura (<xref ref-type="table" rid="tab1">Table 1</xref>).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption><p>Comparison of demographic and disease-related characteristics between subjects with habituation versus dishabituation.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="top">Subjects with habituation (<italic>n</italic>&#x2009;=&#x2009;11)</th>
<th align="center" valign="top">Subjects with dishabituation (<italic>n</italic>&#x2009;=&#x2009;17)</th>
<th align="center" valign="top">Significance <italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Age (years)</td>
<td align="center" valign="top">51.25</td>
<td align="center" valign="top">50.36</td>
<td align="center" valign="top">0.877 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">Migraine days per month</td>
<td align="center" valign="top">7.31</td>
<td align="center" valign="top">7.21</td>
<td align="center" valign="top">0.952 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">Pain intensity (1&#x2013;10)</td>
<td align="center" valign="top">7.13</td>
<td align="center" valign="top">7.04</td>
<td align="center" valign="top">0.899 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">Duration of illness (months)</td>
<td align="center" valign="top">162.57</td>
<td align="center" valign="top">219.00</td>
<td align="center" valign="top">0.375 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">HIT-6</td>
<td align="center" valign="top">62.63</td>
<td align="center" valign="top">63.21</td>
<td align="center" valign="top">0.845 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">MIDAS (score)</td>
<td align="center" valign="top">61.64</td>
<td align="center" valign="top">67.38</td>
<td align="center" valign="top">0.855 (n.s.)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>N, Number; HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment; n.s., not significant (<italic>t</italic>-test; <italic>p</italic>&#x2009;&#x003E;&#x2009;0.05).</p>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="tab2">Table 2</xref> illustrates demographic and disease-related characteristics of subjects with different degrees of afterimage duration. There are no significant differences in these characteristics between subjects with high and low afterimage duration. Among the subjects with long afterimage duration, 55.0% had migraine with aura. Among the subjects with short afterimage duration, 38.5% had a migraine with aura. There is no significant difference in afterimage duration between migraine patients with and without aura (<xref ref-type="table" rid="tab2">Table 2</xref>).</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption><p>Comparison of the demographic and disease-related characteristics between the groups with strong versus less pronounced afterimage duration.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="top">Subjects with long afterimage duration (<italic>n</italic>&#x2009;=&#x2009;11)</th>
<th align="center" valign="top">Subjects with short afterimage duration (<italic>n</italic>&#x2009;=&#x2009;18)</th>
<th align="center" valign="top">Significance <italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Age (years)</td>
<td align="center" valign="top">47.37</td>
<td align="center" valign="top">55.54</td>
<td align="center" valign="top">0.133 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">Migraine days per month</td>
<td align="center" valign="top">7.75</td>
<td align="center" valign="top">7.54</td>
<td align="center" valign="top">0.894 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">Pain intensity (1&#x2013;10)</td>
<td align="center" valign="top">6.94</td>
<td align="center" valign="top">7.31</td>
<td align="center" valign="top">0.577 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">Duration of illness (months)</td>
<td align="center" valign="top">215.50</td>
<td align="center" valign="top">166.15</td>
<td align="center" valign="top">0.449 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">HIT-6</td>
<td align="center" valign="top">66.63</td>
<td align="center" valign="top">62.08</td>
<td align="center" valign="top">0.109 (n.s.)</td>
</tr>
<tr>
<td align="left" valign="top">MIDAS (score)</td>
<td align="center" valign="top">43.23</td>
<td align="center" valign="top">97.75</td>
<td align="center" valign="top">0.083 (n.s.)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>n, Number; HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment; n.s., not significant (<italic>t</italic>-test; <italic>p</italic>&#x2009;&#x003E;&#x2009;0.05).</p>
</table-wrap-foot>
</table-wrap>
<p>Prophylactic agents were used by 14 subjects. Six patients used beta-blockers, five patients used amitriptyline, and three patients used topiramate.</p>
</sec>
<sec id="sec20">
<label>4.2</label>
<title>Drop-out</title>
<p>Data from 29 of the 67 subjects were used for further analysis (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The afterimage duration and iCNV amplitude results of 24 subjects could not be included because the subjects reported a migraine attack within two days before or after the study day. A migraine attack can affect the level of iCNV amplitude and the habituation coefficient (<xref ref-type="bibr" rid="ref18">18</xref>, <xref ref-type="bibr" rid="ref19">19</xref>, <xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref43">43</xref>) as well as the afterimage duration (<xref ref-type="bibr" rid="ref25">25</xref>). Technical problems occurred in ten subjects. Four subjects did not return their questionnaires. No subject reported insufficient visual acuity, which would have prevented evaluation of the afterimage duration.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption><p>Drop-out.</p></caption>
<graphic xlink:href="fneur-15-1401212-g003.tif"/>
</fig>
</sec>
<sec id="sec21">
<label>4.3</label>
<title>Relation between habituation capacity and afterimage duration</title>
<p>To investigate the relationship between afterimage duration characteristics and habituation capacity in migraine patients, subjects were divided into two groups, habituated (habituation coefficient&#x2009;&#x003C;&#x2009;0) and dishabituated (habituation coefficient&#x2009;&#x003E;&#x2009;0), based on their iCNV amplitude-related habituation capacity.</p>
<p>Significant differences (<italic>p</italic>&#x2009;=&#x2009;0.013) in the duration of the afterimage evoked by a black visual stimulus (black circular ring) were detected between subjects with identified habituation and sensitization regarding the iCNV amplitude (<xref ref-type="table" rid="tab3">Table 3</xref>). Afterimages were reported to last for a shorter time in subjects with pronounced habituation (M<sub>afterimage</sub>&#x2009;=&#x2009;5.11&#x2009;s; SD<sub>afterimage</sub>&#x2009;=&#x2009;2.36&#x2009;s) compared to subjects with sensitization (M<sub>afterimage</sub>&#x2009;=&#x2009;8.17&#x2009;s; SD<sub>afterimage</sub>&#x2009;=&#x2009;3.86&#x2009;s) (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption><p>Afterimage duration in subjects with habituation versus dishabituation.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="left" valign="top">Habituation capacity</th>
<th align="center" valign="top">N</th>
<th align="center" valign="top">M</th>
<th align="center" valign="top">SD</th>
<th align="center" valign="top">MD</th>
<th align="center" valign="top"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2">Afterimage duration (in seconds)</td>
<td align="left" valign="top">Dishabituation</td>
<td align="center" valign="top">17</td>
<td align="center" valign="top">8.17</td>
<td align="center" valign="top">3.86</td>
<td align="center" valign="top" rowspan="2">3.06</td>
<td align="center" valign="top" rowspan="2">0.013&#x002A;</td>
</tr>
<tr>
<td align="left" valign="top">Habituation</td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">5.11</td>
<td align="center" valign="top">2.36</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>N, Number of patients; M, mean; SD, standard deviation; MD, Mean difference; <italic>p</italic>, <italic>p</italic>-value. &#x002A;(<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05).</p>
</table-wrap-foot>
</table-wrap>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption><p>Mean and standard deviation of afterimage duration time in migraine patients with habituation and dishabituation. M, Mean; SD, standard deviation.</p></caption>
<graphic xlink:href="fneur-15-1401212-g004.tif"/>
</fig>
<p>As there are only a few studies on the afterimage effect to date and the experimental setup differs, no direct comparisons can be made between the results of different studies.</p>
</sec>
<sec id="sec22">
<label>4.4</label>
<title>Relation between iCNV amplitude and afterimage duration</title>
<p>Amplitudes of the early components of the CNV are compared between subjects with long (&#x2265;6&#x2009;s) and short (&#x003C;6&#x2009;s) afterimage duration. ANOVA revealed a significant difference (<italic>p</italic>&#x2009;=&#x2009;0.011) between the two groups in the amplitude of iCNV (<xref ref-type="table" rid="tab4">Table 4</xref>).</p>
<table-wrap position="float" id="tab4">
<label>Table 4</label>
<caption><p>iCNV amplitude in relation to afterimage duration.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="left" valign="top">Afterimage duration</th>
<th align="center" valign="top">N</th>
<th align="center" valign="top">M</th>
<th align="center" valign="top">SD</th>
<th align="center" valign="top">MD</th>
<th align="center" valign="top"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2">iCNV-Amplitude (in &#x03BC;V)</td>
<td align="left" valign="top">Long</td>
<td align="center" valign="top">18</td>
<td align="center" valign="top">&#x2212;11.59</td>
<td align="center" valign="top">3.17</td>
<td align="center" valign="top" rowspan="2">&#x2212;2.54</td>
<td align="center" valign="top" rowspan="2">0.011&#x002A;</td>
</tr>
<tr>
<td align="left" valign="top">Short</td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">&#x2212;9.05</td>
<td align="center" valign="top">1.79</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>N, Number of patients; M, mean; SD, standard deviation; MD, Mean difference; <italic>p</italic>, <italic>p</italic>-value. &#x002A;(<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05).</p>
</table-wrap-foot>
</table-wrap>
<p>Subjects experiencing long afterimage duration showed significantly higher iCNV amplitudes (M<sub>iCNV</sub>&#x2009;=&#x2009;&#x2212;11.59&#x2009;&#x03BC;V; SD<sub>iCNV</sub>&#x2009;=&#x2009;3.17&#x2009;&#x03BC;V) than subjects reporting an afterimage persisting for less than 6&#x2009;s (M<sub>iCNV</sub>&#x2009;=&#x2009;&#x2212;9.05&#x2009;&#x03BC;V; SD<sub>iCNV</sub>&#x2009;=&#x2009;1.79&#x2009;&#x03BC;V) (<xref ref-type="fig" rid="fig5">Figure 5</xref>). The iCNV values determined in migraine patients are consistent with previous studies. In healthy volunteers, iCNV values of around &#x2212;4.8&#x2009;&#x03BC;V have been measured in previous studies (<xref ref-type="bibr" rid="ref14">14</xref>).</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption><p>Mean and standard deviation of iCNV amplitude in migraine patients with long and short afterimage duration. M, mean; SD, standard deviation.</p></caption>
<graphic xlink:href="fneur-15-1401212-g005.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec23">
<label>5</label>
<title>Discussion</title>
<p>The results confirm the hypothesis of a correlation between the two examined parameters iCNV amplitude and afterimage duration. Long afterimage duration is associated with a high (more negative) iCNV amplitude. This may be related to the pathophysiology of migraine. In addition, the results allow a model of the pathophysiology of migraine to be constructed.</p>
<sec id="sec24">
<label>5.1</label>
<title>Model of the pathophysiology of migraine</title>
<p>The results of several studies can be used to construct a model of the pathomechanism of migraine, supported by the associated pathophysiological correlates (<xref ref-type="fig" rid="fig6">Figure 6</xref>). People with migraine have a lower level of baseline neuronal excitation than healthy people (<xref ref-type="bibr" rid="ref26">26</xref>). This low level of pre-activation allows a greater range of suprathreshold activation before reaching the threshold of inhibitory processes. As a result, the low baseline cortical excitation requires greater synchronous neuronal activity to achieve the onset of the habituation mechanism (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref27">27</xref>). The habituation deficit in migraine patients demonstrated in numerous studies (<xref ref-type="bibr" rid="ref15">15</xref>, <xref ref-type="bibr" rid="ref16">16</xref>, <xref ref-type="bibr" rid="ref56">56</xref>) may thus be related to the low cortical pre-activation level (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref27">27</xref>). Habituation is a natural mechanism that is responsible for a decrease in the intensity of the post-stimulus orienting response when an identical stimulus is repeatedly perceived with persistently the same intensity (<xref ref-type="bibr" rid="ref44">44</xref>). Critically, the habituation process protects the brain from too much information and too much cortical activation. Therefore, reduced habituation capacity and impaired selective information processing lead to increased excitability of cortical neurons (<xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref33">33</xref>, <xref ref-type="bibr" rid="ref44">44</xref>). Another possible explanation for increased cortical excitability is an insufficiency of neuronal mitochondria, which leads to an energy deficit and an insufficient capacity for habituation (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref21">21</xref>, <xref ref-type="bibr" rid="ref57">57</xref>&#x2013;<xref ref-type="bibr" rid="ref59">59</xref>).</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption><p>Model of the pathomechanism of migraine with regard to the migraine phases. The flowchart illustrates a model of the pathomechanism of migraine. Arrows 1&#x2013;5 represent the pathomechanism; arrows 6&#x2013;8 show the pathophysiological origins of the (electrophysiologically) measurable findings in migraine patients. Sources (with attribution to the components in the model): &#x2460; (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref27">27</xref>); &#x2461; (<xref ref-type="bibr" rid="ref44">44</xref>); (<xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref33">33</xref>); &#x2462; (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref45">45</xref>); &#x2463; (<xref ref-type="bibr" rid="ref11">11</xref>, <xref ref-type="bibr" rid="ref46">46</xref>&#x2013;<xref ref-type="bibr" rid="ref55">55</xref>); &#x2464; (<xref ref-type="bibr" rid="ref9">9</xref>); &#x2465; (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref33">33</xref>); &#x2466; (<xref ref-type="bibr" rid="ref33">33</xref>); &#x2467; (<xref ref-type="bibr" rid="ref12">12</xref>).</p></caption>
<graphic xlink:href="fneur-15-1401212-g006.tif"/>
</fig>
<p>Increased cortical neuronal excitability may be responsible for the development of <italic>Cortical Spreading Depression</italic> (CSD). It has been suggested that the high number of de-and repolarizations leads to the accumulation of extracellular potassium, which promotes the development of CSD (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref45">45</xref>). Although CSD occurs concurrently with the aura phase, it is thought to underlie not only the aura symptomatology but also the delayed headache phase of migraine (<xref ref-type="bibr" rid="ref54">54</xref>). Thus, the increased trigeminal nociception caused by vasodilatation and neurogenic inflammation can be understood as a result of <italic>Cortical Spreading Depression</italic> (<xref ref-type="bibr" rid="ref11">11</xref>, <xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref46">46</xref>&#x2013;<xref ref-type="bibr" rid="ref49">49</xref>, <xref ref-type="bibr" rid="ref51">51</xref>&#x2013;<xref ref-type="bibr" rid="ref55">55</xref>).</p>
<p>Consequently, as shown in the flowchart below (<xref ref-type="fig" rid="fig6">Figure 6</xref>), imbalances at the neuronal level lead to changes at the vascular level. It is likely that the link between neuronal and vascular processes plays a crucial role in the pathomechanism of migraine (<xref ref-type="bibr" rid="ref9">9</xref>).</p>
<p>The origins of the pathophysiological correlates can be localized using the model. The cortical habituation deficit and increased neuronal excitability are manifested in the habituation deficit related to iCNV amplitude (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref33">33</xref>) and the increased amplitude of the early CNV component (<xref ref-type="bibr" rid="ref33">33</xref>). It is reasonable to assume that the increased iCNV amplitude in people with migraine is &#x2014; at least in part &#x2014; due to the habituation deficit. The early amplitude of the CNV does not decrease sufficiently during repetitions of the same stimulus. As a consequence of the habituation deficit, the amplitude of iCNV averaged over all trials is increased in migraine patients compared to healthy subjects (<xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref33">33</xref>).</p>
<p>The long afterimage duration in migraine patients can be attributed to increased cortical excitability with reduced baseline activation (<xref ref-type="bibr" rid="ref12">12</xref>). It appears that reduced habituation capacity is not only the cause of a migraine attack, but also of the increased amplitude of iCNV, the habituation deficit associated with iCNV amplitude and the prolonged afterimage latency.</p>
<p>The associations demonstrated in this study are consistent with the results of studies providing evidence for an origin of migraine in an altered pre-activation level (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref27">27</xref>) or altered neuronal homeostasis caused by a neuronal mitochondrial deficit (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref21">21</xref>, <xref ref-type="bibr" rid="ref57">57</xref>&#x2013;<xref ref-type="bibr" rid="ref59">59</xref>). Furthermore, these findings support the hypothesis that the altered CNV parameters (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref33">33</xref>) and the very long afterimage duration (<xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref60">60</xref>) in migraine patients are related to the pathophysiology of migraine. As this study has demonstrated a relationship between afterimage duration and CNV parameters, it is reasonable to conclude that both phenomena may play a crucial role in the study and treatment of migraine.</p>
<p>Consequently, it is reasonable to assume that periodic changes parallel to migraine phases can be detected not only by looking at iCNV amplitude, but also by examining the degree of afterimage duration. The identification of significant correlations between habituation coefficient and afterimage duration, or iCNV amplitude and afterimage duration, suggests parallel periodic changes in these phenomena during a migraine interval.</p>
<p>Previous studies have documented separate observations only for the periodicity of CNV amplitude (<xref ref-type="bibr" rid="ref18">18</xref>, <xref ref-type="bibr" rid="ref19">19</xref>, <xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref43">43</xref>) <italic>or</italic> afterimage duration (<xref ref-type="bibr" rid="ref25">25</xref>). Furthermore, as mentioned above, there are limitations to the interpretation of Luedtke et al.&#x2019;s study on the periodicity of afterimage duration in migraine patients. Therefore, by considering the relationship between CNV parameters and afterimage duration, this study provides complementary findings to previously-published study results.</p>
</sec>
<sec id="sec25">
<label>5.2</label>
<title>Improvement of migraine therapy</title>
<sec id="sec26">
<label>5.2.1</label>
<title>Theory of migraine pathomechanism</title>
<p>An association between afterimage duration and CNV parameters supports the hypothesis of a similar or common origin of increased iCNV amplitude, habituation deficit and highly pronounced afterimage duration in people with migraine. These phenomena can be attributed to increased cortical pre-activation and cortical hyperexcitability. The theory of increased cortical excitability is supported by the results of this study.</p>
</sec>
<sec id="sec27">
<label>5.2.2</label>
<title>Therapy progress monitoring</title>
<p>It is already known that pharmacological therapy can influence the parameters of CNV (<xref ref-type="bibr" rid="ref61">61</xref>&#x2013;<xref ref-type="bibr" rid="ref64">64</xref>). However, CNV assessment is not used as a diagnostic tool or for monitoring disease progression. This is partly due to the time- and personnel-intensive nature of the examination. As afterimage duration correlates with iCNV amplitude and habituation, it can be discussed as an examination tool that can be used for therapy monitoring.</p>
</sec>
<sec id="sec28">
<label>5.2.3</label>
<title>Early detection of a future migraine attack</title>
<p>The predictive value of iCNV amplitude has already been demonstrated in studies, as it can be used to predict an upcoming attack. This knowledge could be used therapeutically, for example, to prevent the development of migraine through early use of relaxation exercises (<xref ref-type="bibr" rid="ref18">18</xref>, <xref ref-type="bibr" rid="ref19">19</xref>). Taking analgesics early, before a migraine attack, may also improve their effectiveness (<xref ref-type="bibr" rid="ref20">20</xref>). From the demonstrated relationship between iCNV amplitude and afterimage duration, we can conclude that afterimage duration could be used to predict a future migraine attack.</p>
<p>Determination of afterimage duration has several advantages compared to CNV examination: It is less extensive, personnel-and time-intensive than the determination of CNV components and does not require extensive technical equipment. Therefore, it is conceivable that the determination of the afterimage duration could be performed independently by the patient at home after sufficient training. In addition, the simplicity of the method allows more frequent and shorter measurement intervals, which can improve the quality of the prediction. An app developed for people with migraine could predict the onset of an upcoming migraine attack (before prodromes occur) by analyzing the afterimage duration, allowing the patient to take a drug or non-drug prophylactic therapy. It may also enable the patient to identify further prodromes, since the time of occurrence of the prodromes can be determined in a comprehensible way by analyzing the afterimage duration.</p>
<p>Finally, as a result of more efficient treatment, medication overuse due to ineffective drug therapy, which can lead to the chronicity of migraine (<xref ref-type="bibr" rid="ref65">65</xref>), can be prevented more often and more effectively. Effective treatment could reduce the direct and indirect costs of the disorder. Moreover, effective treatment can improve the quality of life of migraine patients and reduce their disabilities.</p>
</sec>
</sec>
<sec id="sec29">
<label>5.3</label>
<title>Limitations</title>
<p>The subjects do not represent the average characteristics of the overall population of people with migraine. Patients from the headache center at the University of Rostock Medical Center who were included in this study generally have a disease history of several years, a high number of migraine days and a long duration of a migraine attack. In addition, most patients had been pre-treated with medication. This may have had an effect on CNV parameters (<xref ref-type="bibr" rid="ref61">61</xref>&#x2013;<xref ref-type="bibr" rid="ref64">64</xref>).</p>
<p>Further limitations arise from the examination methods and conditions used in this study, as well as the study design. Considering the periodicity of iCNV parameters (<xref ref-type="bibr" rid="ref18">18</xref>&#x2013;<xref ref-type="bibr" rid="ref20">20</xref>) and the afterimage duration (<xref ref-type="bibr" rid="ref22">22</xref>), the measured values are influenced by both the time of day and the time elapsed since the last attack. We minimized this influence by excluding from the analysis the data of all subjects who had experienced a migraine attack within two days prior to the study.</p>
<p>A separate analysis of the afterimage duration of migraine patients with and without aura was not performed. The existence of these differences can be explained by the fact that the pathomechanisms are likely to be different between migraine patients with and without aura (<xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref21">21</xref>, <xref ref-type="bibr" rid="ref22">22</xref>). Therefore, we cannot exclude the possibility that a study with a larger number of subjects in each group might find differences in afterimage duration or the relationship between it and CNV parameters.</p>
<p>Our study is the first study to investigate the relationship between CNV and the afterimage effect in migraine patients. Due to the exploratory nature of the study, we did not analyze migraine patients with episodic and chronic migraine separately. However, as there may be differences between these two groups, patients with episodic and chronic migraine should be considered separately in the future.</p>
<p>The determination of the afterimage duration is more prone to error than objective measurement methods, as the active cooperation and concentration of the subject is essential. It is therefore likely that the patient&#x2019;s reaction time has an influence on the measured afterimage duration. In addition, afterimage determination can be influenced by movements of the inner eye muscles and blinking (<xref ref-type="bibr" rid="ref42">42</xref>).</p>
</sec>
</sec>
<sec sec-type="conclusions" id="sec30">
<label>6</label>
<title>Conclusion</title>
<p>The prediction of migraine attacks will play a decisive role in future therapy. Our results show that the examination of the afterimage can be suitable for this. Effective prediction enables patients to live a more symptom-free life and prevents excessive use of medication.</p>
<p>The influence of migraine phase, course, and treatment on the duration of afterimages has not yet been studied in detail. Therefore, we suggest that future studies should further investigate the characteristics of afterimage duration in people with migraine. In particular, the prognostic value of the afterimage duration should be investigated using a daily measurement, if possible, to reduce the influence of measurement errors related to the afterimage duration (<xref ref-type="bibr" rid="ref42">42</xref>).</p>
</sec>
<sec sec-type="data-availability" id="sec31">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec sec-type="ethics-statement" id="sec32">
<title>Ethics statement</title>
<p>The studies involving humans were approved by ethics committee of the University of Rostock Medical Center. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec sec-type="author-contributions" id="sec33">
<title>Author contributions</title>
<p>SG: Writing &#x2013; original draft. FR: Writing &#x2013; review &#x0026; editing. TJ: Writing &#x2013; review &#x0026; editing. JS: Software, Writing &#x2013; review &#x0026; editing. JD: Software, Writing &#x2013; review &#x0026; editing. A-KL: Writing &#x2013; review &#x0026; editing. SS: Writing &#x2013; review &#x0026; editing. BH: Writing &#x2013; review &#x0026; editing. WM: Writing &#x2013; review &#x0026; editing. BM: Formal analysis, Writing &#x2013; review &#x0026; editing. PK: Writing &#x2013; review &#x0026; editing. AK: Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec34">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="disclaimer" id="sec35">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coppola</surname> <given-names>G</given-names></name> <name><surname>Di Lorenzo</surname> <given-names>C</given-names></name> <name><surname>Serrao</surname> <given-names>M</given-names></name> <name><surname>Parisi</surname> <given-names>V</given-names></name> <name><surname>Schoenen</surname> <given-names>J</given-names></name> <name><surname>Pierelli</surname> <given-names>F</given-names></name></person-group>. <article-title>Pathophysiological targets for non-pharmacological treatment of migraine. Cephalalgia: an international journal of</article-title>. <source>Headache</source>. (<year>2016</year>) <volume>36</volume>:<fpage>1103</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0333102415620908</pub-id></citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Diener</surname> <given-names>HC</given-names></name> <name><surname>F&#x00F6;rderreuther</surname> <given-names>S</given-names></name> <name><surname>Kropp</surname> <given-names>P</given-names></name></person-group>. <article-title>Therapie der Migr&#x00E4;neattacke und Prophylaxe der Migr&#x00E4;ne. S1-Leitlinie, 2022</article-title> In: <source>Leitlinien f&#x00FC;r Diagnostik und Therapie in der Neurologie, DGN und DMKG</source> (<year>2022</year>) <comment>Verf&#x00FC;gbar unter. Available at:</comment> <ext-link xlink:href="http://www.dgn.org/leitlinien" ext-link-type="uri">www.dgn.org/leitlinien</ext-link></citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feigin</surname> <given-names>VL</given-names></name> <name><surname>Nichols</surname> <given-names>E</given-names></name> <name><surname>Alam</surname> <given-names>T</given-names></name> <name><surname>Bannick</surname> <given-names>MS</given-names></name> <name><surname>Beghi</surname> <given-names>E</given-names></name> <name><surname>Blake</surname> <given-names>N</given-names></name> <etal/></person-group>. <article-title>Global, regional, and national burden of neurological disorders, 1990&#x2013;2016: a systematic analysis for the global burden of disease study 2016</article-title>. <source>Lancet Neurol</source>. (<year>2019</year>) <volume>18</volume>:<fpage>459</fpage>&#x2013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(18)30499-X</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname> <given-names>M</given-names></name> <name><surname>Steiner</surname> <given-names>TJ</given-names></name> <name><surname>Scher</surname> <given-names>AT</given-names></name> <name><surname>Lipton</surname> <given-names>RB</given-names></name></person-group>. <article-title>The global burden of migraine: measuring disability in headache disorders with WHO&#x2019;s classification of functioning, disability and health (ICF)</article-title>. <source>J Headache Pain</source>. (<year>2005</year>) <volume>6</volume>:<fpage>429</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10194-005-0252-4</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breslau</surname> <given-names>N</given-names></name> <name><surname>Davis</surname> <given-names>GC</given-names></name></person-group>. <article-title>Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults</article-title>. <source>J Psychiatr Res</source>. (<year>1993</year>) <volume>27</volume>:<fpage>211</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0022-3956(93)90009-q</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname> <given-names>PJ</given-names></name> <name><surname>Holland</surname> <given-names>PR</given-names></name> <name><surname>Martins-Oliveira</surname> <given-names>M</given-names></name> <name><surname>Hoffmann</surname> <given-names>J</given-names></name> <name><surname>Schankin</surname> <given-names>C</given-names></name> <name><surname>Akerman</surname> <given-names>S</given-names></name></person-group>. <article-title>Pathophysiology of migraine: a disorder of sensory processing</article-title>. <source>Physiol Rev</source>. (<year>2017</year>) <volume>97</volume>:<fpage>553</fpage>&#x2013;<lpage>622</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00034.2015</pub-id></citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mungoven</surname> <given-names>TJ</given-names></name> <name><surname>Henderson</surname> <given-names>LA</given-names></name> <name><surname>Meylakh</surname> <given-names>N</given-names></name></person-group>. <article-title>Chronic migraine pathophysiology and treatment: a review of current perspectives</article-title>. <source>Front Pain Res</source>. (<year>2021</year>) <volume>2</volume>:<fpage>705276</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpain.2021.705276</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dodick</surname> <given-names>DW</given-names></name></person-group>. <article-title>A phase-by-phase review of migraine pathophysiology</article-title>. <source>Headache</source>. (<year>2018</year>) <volume>58</volume>:<fpage>4</fpage>&#x2013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1111/head.13300</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebersberger</surname> <given-names>A</given-names></name></person-group>. <article-title>Pathophysiologie der Migr&#x00E4;ne Erkl&#x00E4;rungsmodelle zur Entstehung von Migr&#x00E4;nekopfschmerz</article-title>. <source>Der Anaesthesist</source>. (<year>2002</year>) <volume>51</volume>:<fpage>661</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00101-002-0342-5</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebersberger</surname> <given-names>A</given-names></name> <name><surname>Averbeck</surname> <given-names>B</given-names></name> <name><surname>Messlinger</surname> <given-names>K</given-names></name> <name><surname>Reeh</surname> <given-names>P</given-names></name></person-group>. <article-title>Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro</article-title>. <source>Neuroscience</source>. (<year>1999</year>) <volume>89</volume>:<fpage>901</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0306-4522(98)00366-2</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x00FC;rks</surname> <given-names>M</given-names></name> <name><surname>Diener</surname> <given-names>C</given-names></name></person-group>. <article-title>Pathophysiologie der Migr&#x00E4;ne im klinischen Kontext</article-title>. <source>Schmerz</source>. (<year>2008</year>) <volume>22</volume>:<fpage>523</fpage>&#x2013;<lpage>6</lpage>, <comment>528-30</comment>. doi: <pub-id pub-id-type="doi">10.1007/s00482-008-0693-1</pub-id></citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname> <given-names>RN</given-names></name></person-group>. <article-title>A diagnostic sign in migraine?</article-title> <source>J R Soc Med</source>. (<year>2001</year>) <volume>94</volume>:<fpage>286</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1177/014107680109400608</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torrente</surname> <given-names>A</given-names></name> <name><surname>Pilati</surname> <given-names>L</given-names></name> <name><surname>Di Marco</surname> <given-names>S</given-names></name> <name><surname>Maccora</surname> <given-names>S</given-names></name> <name><surname>Alonge</surname> <given-names>P</given-names></name> <name><surname>Vassallo</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>OnabotulinumtoxinA modulates visual cortical excitability in chronic migraine: effects of 12-week treatment</article-title>. <source>Toxins</source>. (<year>2022</year>) <volume>15</volume>:<fpage>23</fpage>. doi: <pub-id pub-id-type="doi">10.3390/toxins15010023</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerber</surname> <given-names>WD</given-names></name> <name><surname>Kropp</surname> <given-names>P</given-names></name></person-group>. <article-title>Migraine: a disorder of sensory stimulus modulation? Empirical studies based on contingent negative variation</article-title>. <source>Schmerz</source>. (<year>1993</year>) <volume>7</volume>:<fpage>280</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF02529864</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kropp</surname> <given-names>P</given-names></name> <name><surname>Linstedt</surname> <given-names>U</given-names></name> <name><surname>Gerber</surname> <given-names>WD</given-names></name></person-group>. <article-title>Duration of migraine disease correlates with amplitude and habituation of event-related potentials</article-title>. <source>Schmerz</source>. (<year>2005</year>) <volume>19</volume>:<fpage>489</fpage>&#x2013;<lpage>92</lpage>, <comment>494&#x2013;6</comment>. doi: <pub-id pub-id-type="doi">10.1007/s00482-005-0386-y</pub-id></citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siniatchkin</surname> <given-names>M</given-names></name> <name><surname>Gerber</surname> <given-names>WD</given-names></name></person-group>. <article-title>Die Rolle der Familie in der Entstehung neurophysiologischer Auff&#x00E4;lligkeiten bei Kindern mit Migr&#x00E4;ne [role of family in development of neurophysiological manifestations in children with migraine]</article-title>. <source>Prax Kinderpsychol Kinderpsychiatr</source>. (<year>2002</year>) <volume>51</volume>:<fpage>194</fpage>&#x2013;<lpage>208</lpage>.</citation></ref>
<ref id="ref17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname> <given-names>WG</given-names></name> <name><surname>Cooper</surname> <given-names>R</given-names></name> <name><surname>Aldridge</surname> <given-names>VJ</given-names></name> <name><surname>MCCALLUM</surname> <given-names>WC</given-names></name> <name><surname>Winter</surname> <given-names>AL</given-names></name></person-group>. <article-title>Contingent negative variation: an electric sign of Sensori-motor association and expectancy in the human brain</article-title>. <source>Nature</source>. (<year>1964</year>) <volume>203</volume>:<fpage>380</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1038/203380a0</pub-id></citation></ref>
<ref id="ref18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kropp</surname> <given-names>P</given-names></name> <name><surname>Gerber</surname> <given-names>WD</given-names></name></person-group>. <article-title>Prediction of migraine attacks using a slow cortical potential, the contingent negative variation</article-title>. <source>Neurosci Lett</source>. (<year>1998</year>) <volume>257</volume>:<fpage>73</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0304-3940(98)00811-8</pub-id></citation></ref>
<ref id="ref19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kropp</surname> <given-names>P</given-names></name> <name><surname>Gerber</surname> <given-names>WD</given-names></name></person-group>. <article-title>Slow cortical potentials in migraine. Predictive value and possible novel therapeutic strategies to prevent an attack</article-title>. <source>Funct Neurol</source>. (<year>2005</year>) <volume>20</volume>:<fpage>193</fpage>&#x2013;<lpage>7</lpage>. PMID: <pub-id pub-id-type="pmid">16483460</pub-id></citation></ref>
<ref id="ref20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luciani</surname> <given-names>R</given-names></name> <name><surname>Carter</surname> <given-names>D</given-names></name> <name><surname>Mannix</surname> <given-names>L</given-names></name> <name><surname>Hemphill</surname> <given-names>M</given-names></name> <name><surname>Diamond</surname> <given-names>M</given-names></name> <name><surname>Cady</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Prevention of migraine during prodrome with naratriptan. Cephalalgia: an international journal of</article-title>. <source>Headache</source>. (<year>2000</year>) <volume>20</volume>:<fpage>122</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1468-2982.2000.00030.x</pub-id></citation></ref>
<ref id="ref21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname> <given-names>AJ</given-names></name></person-group>. <article-title>Increased visual after-effects following pattern adaptation in migraine: a lack of intracortical excitation? Brain: a</article-title>. <source>J Neurol</source>. (<year>2001</year>) <volume>124</volume>:<fpage>2310</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/124.11.2310</pub-id></citation></ref>
<ref id="ref22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname> <given-names>AJ</given-names></name></person-group>. <article-title>Local and global motion after-effects are both enhanced in migraine, and the underlying mechanisms differ across cortical areasa</article-title>. <source>Brain J Neurol</source>. (<year>2006</year>) <volume>129</volume>:<fpage>1833</fpage>&#x2013;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awl124</pub-id></citation></ref>
<ref id="ref23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>B</given-names></name> <name><surname>Holm</surname> <given-names>L</given-names></name> <name><surname>Bao</surname> <given-names>M</given-names></name></person-group>. <article-title>Cortical mechanisms for afterimage formation: evidence from interocular grouping</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>41101</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep41101</pub-id></citation></ref>
<ref id="ref24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>BN</given-names></name> <name><surname>McKendrick</surname> <given-names>AM</given-names></name> <name><surname>Vingrys</surname> <given-names>AJ</given-names></name></person-group>. <article-title>Simultaneous retinal and cortical visually evoked electrophysiological responses in between migraine attacks</article-title>. <source>Cephalalgia</source>. (<year>2012</year>) <volume>32</volume>:<fpage>896</fpage>&#x2013;<lpage>907</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0333102412453953</pub-id></citation></ref>
<ref id="ref25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luedtke</surname> <given-names>K</given-names></name> <name><surname>Schulte</surname> <given-names>LH</given-names></name> <name><surname>May</surname> <given-names>A</given-names></name></person-group>. <article-title>Visual processing in migraineurs depends on the migraine cycle</article-title>. <source>Ann Neurol</source>. (<year>2019</year>) <volume>85</volume>:<fpage>280</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.25398</pub-id></citation></ref>
<ref id="ref26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini</surname> <given-names>A</given-names></name> <name><surname>Schoenen</surname> <given-names>J</given-names></name></person-group>. <article-title>The electrophysiology of migraine</article-title>. <source>Curr Opin Neurol</source>. (<year>2003</year>) <volume>16</volume>:<fpage>327</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.wco.0000073945.19076.1f</pub-id></citation></ref>
<ref id="ref27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname> <given-names>JR</given-names></name> <name><surname>Irwin</surname> <given-names>DA</given-names></name></person-group>. <article-title>Anxiety, stress, and the contingent negative variation</article-title>. <source>Arch Gen Psychiatry</source>. (<year>1973</year>) <volume>29</volume>:<fpage>538</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archpsyc.1973.04200040080013</pub-id></citation></ref>
<ref id="ref28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brighina</surname> <given-names>F</given-names></name> <name><surname>Palermo</surname> <given-names>A</given-names></name> <name><surname>Fierro</surname> <given-names>B</given-names></name></person-group>. <article-title>Cortical inhibition and habituation to evoked potentials: relevance for pathophysiology of migraine</article-title>. <source>J Headache Pain</source>. (<year>2009</year>) <volume>10</volume>:<fpage>77</fpage>&#x2013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10194-008-0095-x</pub-id></citation></ref>
<ref id="ref29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname> <given-names>B</given-names></name> <name><surname>Keller</surname> <given-names>A</given-names></name> <name><surname>M&#x00FC;ller</surname> <given-names>B</given-names></name> <name><surname>W&#x00F6;hlbier</surname> <given-names>HG</given-names></name> <name><surname>Kropp</surname> <given-names>P</given-names></name></person-group>. <article-title>Progressive muscle relaxation according to Jacobson for migraine prophylaxis: clinical effectiveness and mode of action</article-title>. <source>Schmerz</source>. (<year>2018</year>) <volume>32</volume>:<fpage>250</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00482-018-0305-7</pub-id>, PMID: <pub-id pub-id-type="pmid">29974213</pub-id></citation></ref>
<ref id="ref30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoenen</surname> <given-names>J</given-names></name> <name><surname>Ambrosini</surname> <given-names>A</given-names></name> <name><surname>S&#x00E1;ndor</surname> <given-names>PS</given-names></name> <name><surname>Maertens de Noordhout</surname> <given-names>A</given-names></name></person-group>. <article-title>Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their pathophysiologic significance</article-title>. <source>Clin Neurophysiol</source>. (<year>2003</year>) <volume>114</volume>:<fpage>955</fpage>&#x2013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1388-2457(03)00024-5</pub-id></citation></ref>
<ref id="ref31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoenen</surname> <given-names>J</given-names></name> <name><surname>Timsit-Berthier</surname> <given-names>M</given-names></name></person-group>. <article-title>Contingent negative variation: methods and potential interest in headache</article-title>. <source>Cephalalgia</source>. (<year>1993</year>) <volume>13</volume>:<fpage>28</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1468-2982.1993.1301028.x</pub-id></citation></ref>
<ref id="ref32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kropp</surname> <given-names>P</given-names></name> <name><surname>Gerber</surname> <given-names>WD</given-names></name></person-group>. <article-title>Contingent negative variation during migraine attack and interval: evidence for normalization of slow cortical potentials during the attack</article-title>. <source>Cephalalgia</source>. (<year>1995</year>) <volume>15</volume>:<fpage>123</fpage>&#x2013;<lpage>8</lpage>. <comment>discussion: 78&#x2013;9</comment>. doi: <pub-id pub-id-type="doi">10.1046/j.1468-2982.1995.015002123.x</pub-id></citation></ref>
<ref id="ref33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kropp</surname> <given-names>P</given-names></name> <name><surname>Siniatchkin</surname> <given-names>M</given-names></name> <name><surname>Stephani</surname> <given-names>U</given-names></name> <name><surname>Gerber</surname> <given-names>WD</given-names></name></person-group>. <article-title>Migraine &#x2013; evidence for a disturbance of cerebral maturation in man?</article-title> <source>Neurosci Lett</source>. (<year>1999</year>) <volume>276</volume>:<fpage>181</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0304-3940(99)00822-8</pub-id>, PMID: <pub-id pub-id-type="pmid">10612635</pub-id></citation></ref>
<ref id="ref34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname> <given-names>R</given-names></name> <name><surname>Jakubowski</surname> <given-names>M</given-names></name> <name><surname>Garcia-Nicas</surname> <given-names>E</given-names></name> <name><surname>Kainz</surname> <given-names>V</given-names></name> <name><surname>Bajwa</surname> <given-names>Z</given-names></name> <name><surname>Hargreaves</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Thalamic sensitization transforms localized pain into widespread allodynia</article-title>. <source>Ann Neurol</source>. (<year>2010</year>) <volume>68</volume>:<fpage>81</fpage>&#x2013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.21994</pub-id></citation></ref>
<ref id="ref35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname> <given-names>AJ</given-names></name> <name><surname>Siniatchkin</surname> <given-names>M</given-names></name></person-group>. <article-title>Visual pattern adaptation in subjects with photoparoxysmal EEG response: evidence for increased visual cortical excitability</article-title>. <source>Invest Ophthalmol Vis Sci</source>. (<year>2009</year>) <volume>50</volume>:<fpage>1470</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1167/iovs.07-1462</pub-id></citation></ref>
<ref id="ref36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname> <given-names>HE</given-names></name> <name><surname>Park</surname> <given-names>JW</given-names></name> <name><surname>Kim</surname> <given-names>Y</given-names></name> <name><surname>Lee</surname> <given-names>KS</given-names></name></person-group>. <article-title>Headache impact Test-6 (HIT-6) scores for migraine patients: their relation to disability as measured from a headache diary</article-title>. <source>J. Clin. Neurol.</source> (<year>2008</year>) <volume>4</volume>:<fpage>158</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.3988/jcn.2008.4.4.158</pub-id></citation></ref>
<ref id="ref37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Houts</surname> <given-names>CR</given-names></name> <name><surname>Wirth</surname> <given-names>RJ</given-names></name> <name><surname>McGinley</surname> <given-names>JS</given-names></name> <name><surname>Gwaltney</surname> <given-names>C</given-names></name> <name><surname>Kassel</surname> <given-names>E</given-names></name> <name><surname>Snapinn</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Content validity of HIT-6 as a measure of headache impact in people with migraine: a narrative review</article-title>. <source>Headache</source>. (<year>2020</year>) <volume>60</volume>:<fpage>28</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1111/head.13701</pub-id></citation></ref>
<ref id="ref38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sauro</surname> <given-names>KM</given-names></name> <name><surname>Rose</surname> <given-names>MS</given-names></name> <name><surname>Becker</surname> <given-names>WJ</given-names></name> <name><surname>Christie</surname> <given-names>SN</given-names></name> <name><surname>Giammarco</surname> <given-names>R</given-names></name> <name><surname>Mackie</surname> <given-names>GF</given-names></name> <etal/></person-group>. <article-title>HIT-6 and MIDAS as measures of headache disability in a headache referral population</article-title>. <source>Headache</source>. (<year>2010</year>) <volume>50</volume>:<fpage>383</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1526-4610.2009.01544.x</pub-id></citation></ref>
<ref id="ref39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jasper</surname> <given-names>HH</given-names></name></person-group>. <article-title>The ten-twenty electrode system of the international federation</article-title>. <source>Electroencephalogr Clin Neurophysiol</source>. (<year>1958</year>) <volume>10</volume>:<fpage>371</fpage>&#x2013;<lpage>5</lpage>.</citation></ref>
<ref id="ref40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jasper</surname> <given-names>H. H.</given-names></name> <name><surname>Carmichael</surname> <given-names>L.</given-names></name></person-group> (<year>1935</year>). <article-title>Electrical potentials from the intact human brain</article-title>. <source>Science</source> <volume>81</volume>(2089), <fpage>51</fpage>&#x2013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.81.2089.51</pub-id></citation></ref>
<ref id="ref41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>B&#x00F6;cker</surname> <given-names>KB</given-names></name> <name><surname>Timsit-Berthier</surname> <given-names>M</given-names></name> <name><surname>Schoenen</surname> <given-names>J</given-names></name> <name><surname>Brunia</surname> <given-names>CH</given-names></name></person-group>. <article-title>Contingent negative variation in migraine</article-title>. <source>Headache</source>. (<year>1990</year>) <volume>30</volume>:<fpage>604</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1526-4610.1990.hed3009604.x</pub-id></citation></ref>
<ref id="ref42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname> <given-names>G</given-names></name> <name><surname>Sumner</surname> <given-names>P</given-names></name> <name><surname>Bompas</surname> <given-names>A</given-names></name></person-group>. <article-title>The effect of eye movements and blinks on afterimage appearance and duration</article-title>. <source>J Vis</source>. (<year>2015</year>) <volume>15</volume>:<fpage>20</fpage>. doi: <pub-id pub-id-type="doi">10.1167/15.3.20</pub-id></citation></ref>
<ref id="ref43"><label>43.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>G&#x00F6;bel</surname> <given-names>H</given-names></name></person-group>. <source>Migr&#x00E4;ne. Diagnostik Therapie Pr&#x00E4;vention (SpringerLink B&#x00FC;cher)</source>. <publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer Berlin Heidelberg</publisher-name> (<year>2012</year>).</citation></ref>
<ref id="ref44"><label>44.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Birbaumer</surname> <given-names>N</given-names></name> <name><surname>Schmidt</surname> <given-names>RF</given-names></name></person-group>. <source>Biologische Psychologie (Springer-Lehrbuch, 7., &#x00FC;berarbeitete und erg&#x00E4;nzte Auflage)</source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name> (<year>2018</year>) <comment>Available at:</comment> <ext-link xlink:href="http://www.springer.com/" ext-link-type="uri">http://www.springer.com/</ext-link>.</citation></ref>
<ref id="ref45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desroches</surname> <given-names>M</given-names></name> <name><surname>Faugeras</surname> <given-names>O</given-names></name> <name><surname>Krupa</surname> <given-names>M</given-names></name> <name><surname>Mantegazza</surname> <given-names>M</given-names></name></person-group>. <article-title>Modeling cortical spreading depression induced by the hyperactivity of interneurons</article-title>. <source>J Comput Neurosci</source>. (<year>2019</year>) <volume>47</volume>:<fpage>125</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10827-019-00730-8</pub-id></citation></ref>
<ref id="ref46"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arngrim</surname> <given-names>N</given-names></name> <name><surname>Hougaard</surname> <given-names>A</given-names></name> <name><surname>Ahmadi</surname> <given-names>K</given-names></name> <name><surname>Vestergaard</surname> <given-names>MB</given-names></name> <name><surname>Schytz</surname> <given-names>HW</given-names></name> <name><surname>Amin</surname> <given-names>FM</given-names></name> <etal/></person-group>. <article-title>Heterogenous migraine aura symptoms correlate with visual cortex functional magnetic resonance imaging responses</article-title>. <source>Ann Neurol</source>. (<year>2017</year>) <volume>82</volume>:<fpage>925</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.25096</pub-id></citation></ref>
<ref id="ref47"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowyer</surname> <given-names>SM</given-names></name> <name><surname>Aurora</surname> <given-names>KS</given-names></name> <name><surname>Moran</surname> <given-names>JE</given-names></name> <name><surname>Tepley</surname> <given-names>N</given-names></name> <name><surname>Welch</surname> <given-names>KM</given-names></name></person-group>. <article-title>Magnetoencephalographic fields from patients with spontaneous and induced migraine aura</article-title>. <source>Ann Neurol</source>. (<year>2001</year>) <volume>50</volume>:<fpage>582</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.1293</pub-id></citation></ref>
<ref id="ref48"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coppola</surname> <given-names>G</given-names></name> <name><surname>Parisi</surname> <given-names>V</given-names></name> <name><surname>Di Renzo</surname> <given-names>A</given-names></name> <name><surname>Pierelli</surname> <given-names>F</given-names></name></person-group>. <article-title>Cortical pain processing in migraine</article-title>. <source>J Neural Trans</source>. (<year>2020</year>) <volume>127</volume>:<fpage>551</fpage>&#x2013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00702-019-02089-7</pub-id></citation></ref>
<ref id="ref49"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cutrer</surname> <given-names>FM</given-names></name> <name><surname>Huerter</surname> <given-names>K</given-names></name></person-group>. <article-title>Migraine aura</article-title>. <source>Neurologist</source>. (<year>2007</year>) <volume>13</volume>:<fpage>118</fpage>&#x2013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.nrl.0000252943.82792.38</pub-id></citation></ref>
<ref id="ref50"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hadjikhani</surname> <given-names>N</given-names></name> <name><surname>Sanchez Del Rio</surname> <given-names>M</given-names></name> <name><surname>Wu</surname> <given-names>O</given-names></name> <name><surname>Schwartz</surname> <given-names>D</given-names></name> <name><surname>Bakker</surname> <given-names>D</given-names></name> <name><surname>Fischl</surname> <given-names>B</given-names></name> <etal/></person-group>. <article-title>Mechanisms of migraine aura revealed by functional MRI in human visual cortex</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2001</year>) <volume>98</volume>:<fpage>4687</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.071582498</pub-id></citation></ref>
<ref id="ref51"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname> <given-names>M</given-names></name></person-group>. <article-title>Pathophysiology of the migraine aura. The spreading depression theory. Brain: a</article-title>. <source>J Neurol</source>. (<year>1994</year>) <volume>117</volume>:<fpage>199</fpage>&#x2013;<lpage>210</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/117.1.199</pub-id></citation></ref>
<ref id="ref52"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x00FC;rks</surname> <given-names>M</given-names></name></person-group>. <article-title>Was ist Migr&#x00E4;ne?</article-title> <source>Der Nervenarzt</source>. (<year>2009</year>) <volume>80</volume>:<fpage>1154</fpage>&#x2013;<lpage>1156&#x2013;9</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00115-009-2704-6</pub-id></citation></ref>
<ref id="ref53"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>JM</given-names></name> <name><surname>Bradley</surname> <given-names>DP</given-names></name> <name><surname>James</surname> <given-names>MF</given-names></name> <name><surname>Huang</surname> <given-names>CL-H</given-names></name></person-group>. <article-title>Physiological studies of cortical spreading depression</article-title>. <source>Biol Rev Camb Philos Soc</source>. (<year>2006</year>) <volume>81</volume>:<fpage>457</fpage>&#x2013;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S1464793106007081</pub-id></citation></ref>
<ref id="ref54"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name> <name><surname>Levy</surname> <given-names>D</given-names></name> <name><surname>Noseda</surname> <given-names>R</given-names></name> <name><surname>Kainz</surname> <given-names>V</given-names></name> <name><surname>Jakubowski</surname> <given-names>M</given-names></name> <name><surname>Burstein</surname> <given-names>R</given-names></name></person-group>. <article-title>Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura</article-title>. <source>J Neurosci Off J Soc Neurosci</source>. (<year>2010</year>) <volume>30</volume>:<fpage>8807</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0511-10.2010</pub-id></citation></ref>
<ref id="ref55"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kissoon</surname> <given-names>NR</given-names></name> <name><surname>Cutrer</surname> <given-names>FM</given-names></name></person-group>. <article-title>Aura and Other neurologic dysfunction in or with migraine</article-title>. <source>Headache</source>. (<year>2017</year>) <volume>57</volume>:<fpage>1179</fpage>&#x2013;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1111/head.13101</pub-id></citation></ref>
<ref id="ref56"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kropp</surname> <given-names>P</given-names></name> <name><surname>Wallasch</surname> <given-names>T-M</given-names></name> <name><surname>M&#x00FC;ller</surname> <given-names>B</given-names></name> <name><surname>Meyer</surname> <given-names>B</given-names></name> <name><surname>Darabaneanu</surname> <given-names>S</given-names></name> <name><surname>Bosse</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Disease duration of episodic migraine correlates with modified amplitudes and habituation of contingent negative variation</article-title>. <source>J Neural Trans</source>. (<year>2015</year>) <volume>122</volume>:<fpage>877</fpage>&#x2013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00702-014-1345-5</pub-id>, PMID: <pub-id pub-id-type="pmid">25432434</pub-id></citation></ref>
<ref id="ref57"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname> <given-names>EC</given-names></name> <name><surname>Lisicki</surname> <given-names>M</given-names></name> <name><surname>Fischer</surname> <given-names>D</given-names></name> <name><surname>S&#x00E1;ndor</surname> <given-names>PS</given-names></name> <name><surname>Schoenen</surname> <given-names>J</given-names></name></person-group>. <article-title>The metabolic face of migraine - from pathophysiology to treatment</article-title>. <source>Nat Rev Neurol</source>. (<year>2019</year>) <volume>15</volume>:<fpage>627</fpage>&#x2013;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41582-019-0255-4</pub-id></citation></ref>
<ref id="ref58"><label>58.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname> <given-names>KM</given-names></name> <name><surname>Levine</surname> <given-names>SR</given-names></name> <name><surname>D&#x2019;Andrea</surname> <given-names>G</given-names></name> <name><surname>Schultz</surname> <given-names>LR</given-names></name> <name><surname>Helpern</surname> <given-names>JA</given-names></name></person-group>. <article-title>Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy</article-title>. <source>Neurology</source>. (<year>1989</year>) <volume>39</volume>:<fpage>538</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.39.4.538</pub-id></citation></ref>
<ref id="ref59"><label>59.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname> <given-names>KM</given-names></name> <name><surname>Ramadan</surname> <given-names>NM</given-names></name></person-group>. <article-title>Mitochondria, magnesium and migraine</article-title>. <source>J Neurol Sci</source>. (<year>1995</year>) <volume>134</volume>:<fpage>9</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0022-510X(95)00196-1</pub-id></citation></ref>
<ref id="ref60"><label>60.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname> <given-names>SK</given-names></name> <name><surname>Cao</surname> <given-names>Y</given-names></name> <name><surname>Bowyer</surname> <given-names>SM</given-names></name> <name><surname>Welch</surname> <given-names>KM</given-names></name></person-group>. <article-title>The occipital cortex is hyperexcitable in migraine: experimental evidence</article-title>. <source>Headache</source>. (<year>1999</year>) <volume>39</volume>:<fpage>469</fpage>&#x2013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1526-4610.1999.3907469.x</pub-id></citation></ref>
<ref id="ref61"><label>61.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname> <given-names>I</given-names></name></person-group>. <article-title>Contingent negative variation in migraine: effect of beta blocker therapy</article-title>. <source>Clin EEG</source>. (<year>1999</year>) <volume>30</volume>:<fpage>21</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1177/155005949903000109</pub-id></citation></ref>
<ref id="ref62"><label>62.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siniatchkin</surname> <given-names>M</given-names></name> <name><surname>Andrasik</surname> <given-names>F</given-names></name> <name><surname>Kropp</surname> <given-names>P</given-names></name> <name><surname>Niederberger</surname> <given-names>U</given-names></name> <name><surname>Strenge</surname> <given-names>H</given-names></name> <name><surname>Averkina</surname> <given-names>N</given-names></name> <etal/></person-group>. <article-title>Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study</article-title>. <source>Cephalalgia</source>. (<year>2007</year>) <volume>27</volume>:<fpage>1024</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1468-2982.2007.01377.x</pub-id></citation></ref>
<ref id="ref63"><label>63.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tommaso</surname> <given-names>M.</given-names></name> <name><surname>Guido</surname> <given-names>M.</given-names></name> <name><surname>Sardaro</surname> <given-names>M.</given-names></name> <name><surname>Serpino</surname> <given-names>C.</given-names></name> <name><surname>Vecchio</surname> <given-names>E.</given-names></name> <name><surname>Stefano</surname> <given-names>G.</given-names> <prefix>De</prefix></name> <etal/></person-group>. (<year>2008</year>). <article-title>Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients</article-title>. <source>Neurosci Lett</source>, <volume>442</volume>, <fpage>81</fpage>&#x2013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neulet.2008.06.076</pub-id></citation></ref>
<ref id="ref64"><label>64.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoenen</surname> <given-names>J</given-names></name> <name><surname>Noordhout</surname> <given-names>AM</given-names></name> <name><surname>Timsit-Berthier</surname> <given-names>M</given-names></name> <name><surname>Timsit</surname> <given-names>M</given-names></name></person-group>. <article-title>Contingent negative variation and efficacy of beta-blocking agents in migraine</article-title>. <source>Cephalalgia</source>. (<year>1986</year>) <volume>6</volume>:<fpage>229</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1468-2982.1986.0604229.x</pub-id></citation></ref>
<ref id="ref65"><label>65.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holle-Lee</surname> <given-names>D</given-names></name> <name><surname>N&#x00E4;gel</surname> <given-names>S</given-names></name> <name><surname>Gaul</surname> <given-names>C</given-names></name></person-group>. <article-title>Therapie der Migr&#x00E4;ne</article-title>. <source>Der Nervenarzt</source>. (<year>2017</year>) <volume>88</volume>:<fpage>929</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00115-017-0338-7</pub-id></citation></ref>
</ref-list>
</back>
</article>
